Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc cut its stake in Teva by 79.7% in Q4, selling 655,837 shares and leaving it with 167,009 shares valued at about $5.21 million.
• Company insiders have been heavy sellers recently—total insider sales of 920,901 shares worth roughly $30.06 million in the last three months (e.g., Mark Sabag sold 62,102 shares for ~$1.87 million); insiders now own about 0.49% of the stock.
• Teva reported a quarterly EPS beat ($0.96 vs. $0.65) and raised FY2026 guidance to 2.57–2.77 EPS, while analysts have largely upgraded targets and the consensus rating is a "Moderate Buy" with an average price target of $37.67.

Aberdeen Group plc decreased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 79.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,009 shares of the company's stock after selling 655,837 shares during the quarter. Aberdeen Group plc's holdings in Teva Pharmaceutical Industries were worth $5,212,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TEVA. Wealth Enhancement Advisory Services LLC raised its position in shares of Teva Pharmaceutical Industries by 3.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company's stock worth $382,000 after purchasing an additional 379 shares during the period. Howard Bailey Securities LLC raised its position in shares of Teva Pharmaceutical Industries by 3.5% during the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company's stock worth $292,000 after purchasing an additional 494 shares during the period. ASR Vermogensbeheer N.V. raised its position in shares of Teva Pharmaceutical Industries by 1.6% during the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company's stock worth $645,000 after purchasing an additional 515 shares during the period. CIBC Private Wealth Group LLC raised its position in shares of Teva Pharmaceutical Industries by 15.5% during the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company's stock worth $81,000 after purchasing an additional 540 shares during the period. Finally, Retirement Planning Co of New England Inc. raised its position in shares of Teva Pharmaceutical Industries by 1.8% during the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company's stock worth $671,000 after purchasing an additional 588 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 62,102 shares of the company's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the sale, the insider owned 224,940 shares in the company, valued at $6,779,691.60. This represents a 21.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Placid Jover sold 14,150 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $448,130.50. Following the sale, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. The trade was a 67.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.49% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $30.50 on Thursday. The business has a 50-day simple moving average of $31.99 and a two-hundred day simple moving average of $28.02. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $37.35. The stock has a market cap of $35.07 billion, a PE ratio of 25.42, a PEG ratio of 10.13 and a beta of 0.76. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the previous year, the company posted $0.71 EPS. The business's revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on TEVA. Jefferies Financial Group increased their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 16th. Barclays lifted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday, January 30th. Wall Street Zen raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 31st. Finally, Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.